Mabpharm Limited, a Taizhou, Jiangsu Province-based biotechnology company, has filed for an initial public offering in Hong Kong, becoming the latest Chinese biotech firm rushing for a Hong Kong IPO.  Since the Hong Kong bourse amended rules to permit listings of biotech companies that do not meet the Main Board’s financial eligibility tests in April, it has attracted several Chinese biotech firms including Suzhou-based biopharmaceutical company Ascentage Pharma Group International and Hangzhou-based Ascletis Pharma. Founded in 2015, Mabpharm focuses on the research, development, …

CDH Investments-backed Chinese Biotechnology Firm Mabpharm Files For Hong Kong IPO appeared first on China Money Network.


Visit the original source and full text: China Money Network